Gilead Prices $2 Billion of Senior Unsecured Notes
- Gilead Sciences successfully priced $2 billion senior unsecured notes in a public offering.
- None.
Gilead intends to use the net proceeds from this offering for general corporate purposes.
Barclays Capital Inc. and Citigroup Global Markets Inc. are acting as lead joint book-running managers in the offering. The offering of the securities is being made only by means of a prospectus supplement and the accompanying base prospectus, which is filed as part of Gilead’s effective shelf registration statement on Form S-3 (File No. 333-273745), copies of which may be obtained from:
Barclays Capital Inc. c/o Broadridge Financial Solutions, 1155 Long Island Avenue
(888) 603-5847 |
|
Citigroup Global Markets Inc. c/o Broadridge Financial Solutions, 1155 Long Island Avenue
(800) 831-9146 Email: prospectus@citi.com |
An electronic copy of the prospectus supplement and the accompanying base prospectus and other documents Gilead has filed with the
About Gilead Sciences
Gilead Sciences, Inc. is a biopharmaceutical company that has pursued and achieved breakthroughs in medicine for more than three decades, with the goal of creating a healthier world for all people. The company is committed to advancing innovative medicines to prevent and treat life-threatening diseases, including HIV, viral hepatitis, COVID-19, and cancer. Gilead operates in more than 35 countries worldwide, with headquarters in
Forward-Looking Statements
This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to risks, uncertainties and other factors, including the current market demand for these types of securities and the securities of Gilead and Gilead’s ability to consummate the offering in the currently anticipated timeframe or at all. These and other risks, uncertainties and other factors are described in detail in Gilead’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2023, as filed with the
View source version on businesswire.com: https://www.businesswire.com/news/home/20230907463986/en/
Jacquie Ross, Investors
investor_relations@gilead.com
Ashleigh Koss, Media
public_affairs@gilead.com
Source: Gilead Sciences, Inc.